Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hyperfine reports Q4 revenue of $1.4M, eyes $14M revenue in 2023

Hyperfine's Q4 2022 earnings call highlighted financial performance, strategic achievements in 2022, challenges in net losses and expenses, and opportunities for revenue growth and expansion in 2023. The company's focus on innovation, partnerships, and commercial progress underpins its outlook for the coming year.

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. continues global expansion by entering into distribution partnership with Radiosurgery Global, Ltd. to bring Swoop® system to India.

Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

PEDEVCO

If you have some spare change jingling in your pocket, it might be worth considering investing that money in penny stocks with good upside potential. The penny stocks on this list are each worth less than $1 as of writing, and I believe many of them could be multibaggers if the stars align favorably.

The Dollar Menu Portfolio: 7 Penny Stocks to Buy With Spare Change

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Jefferies Global Healthcare Conference.

Hyperfine, Inc. to Present at the Jefferies Global Healthcare Conference

LAS VEGAS--(BUSINESS WIRE)--The 2024 ASNR Annual Meeting had a strong focus on Alzheimer's disease care and growing excitement about ultra-low-field MRI.

Hyperfine, Inc. Celebrates ASNR 2024

Hyperfine, Inc. (NASDAQ:HYPR ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Operator Good afternoon, and welcome to the Hyperfine's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.

Hyperfine, Inc. (HYPR) Q1 2024 Earnings Call Transcript

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

Hyperfine, Inc. (HYPR) Reports Q1 Loss, Tops Revenue Estimates

GUILFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update.

Hyperfine, Inc. Reports First Quarter 2024 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to expand global market reach with appointment of international distributors in key European markets.

Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets

Hyperfine (HYPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Hyperfine, Inc. (HYPR) Report Negative Earnings Next Week? What You Should Know

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce first quarter 2024 financial results on May 13, 2024.

Hyperfine, Inc. to Announce First Quarter 2024 Financial Results on May 13, 2024

Hyperfine (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -19% in 4 Weeks, Here's Why Hyperfine (HYPR) Looks Ripe for a Turnaround

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. at ISMRM with 17 abstracts assessing the potential of using Swoop® System images across multiple care settings and clinical conditions.

Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions

GUILFORD, Conn.--(BUSINESS WIRE)--Leading institutions enroll first Alzheimer's patients receiving amyloid-targeting therapy in CARE PMR study.

Leading Institutions Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study

Hyperfine, Inc. (HYPR) Q4 2023 Earnings Call Transcript

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.19 per share a year ago.

Hyperfine, Inc. (HYPR) Reports Q4 Loss, Lags Revenue Estimates

GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2023 financial results and provided a business update.

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. collaborates with King's College London to demonstrate the Swoop® system and UNITY Project to The Princess Royal.

Hyperfine, Inc. Collaborates with King's College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce fourth quarter and full year 2023 financial results on March 21, 2024.

Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Oppenheimer 34th Annual Healthcare Conference.

Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference

GUILFORD, Conn. & ORLANDO, Fla.--(BUSINESS WIRE)--Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes.

Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. presents data at 2024 International Stroke Conference and provides an update on enrollment in ACTION PMR stroke observational study.

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. launches AI-powered brain imaging software for enhanced image quality and ease of use.

Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces presentations on clinical advancements at RSNA 2023.

Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Piper Sandler 35th annual healthcare conference.

Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

Hyperfine, Inc. (NASDAQ:HYPR ) Q3 2023 Earnings Call November 9, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Neil Chatterji - B. Riley Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2023 Earnings Conference Call.

News for Hyperfine Stock (HYPR)